Results 21 to 30 of about 171,176 (147)

Sodium Oxybate: a Substitute for Alcohol?

European Psychiatry, 2022
Gamma-hydroxybutyrate (GHB) is a neurotransmitter found naturally in the human brain. Sodium oxybate (SO) is the sodium salt of GHB. In 2000 GHB was classified a Schedule I controlled substance, while SO became a Schedule III controlled substance for ...
A. Gual, H. López-Pelayo, P. Bruguera, L. Miquel   +3 more
doaj   +1 more source

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists

Neurologijos seminarai, 2020
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė, R. Masaitienė   +1 more
doaj   +1 more source

Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective

Nature and Science of Sleep, 2023
Asim Roy,1 Diane Ito,2 Susan Morris,3 Shawn Candler,4 Judi Profant,3 Charles Bae5 1Ohio Sleep Medicine Institute, Dublin, OH, USA; 2Stratevi LLC, Santa Monica, CA, USA; 3Jazz Pharmaceuticals, Palo Alto, CA, USA; 4Jazz Pharmaceuticals, Philadelphia, PA ...
Roy A, Ito D, Morris S, Candler S, Profant J, Bae C   +5 more
doaj  

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union

Drugs - Real World Outcomes, 2020
Background Sodium oxybate (Xyrem®), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system ...
Alex Iranzo, Pedro Serralheiro, Jan-Christof Schuller, Anne-Françoise Schlit, Jürgen W. G. Bentz   +4 more
doaj   +1 more source

Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)

Nature and Science of Sleep, 2023
Logan Douglas Schneider,1 Joanne Stevens,2 Aatif M Husain,3 Diane Ito,4 Douglas S Fuller,5 Phyllis C Zee,6 Wayne Macfadden2 1Stanford University Sleep Medicine Center, Stanford University School of Medicine, Stanford, CA, USA; 2Global Medical Affairs ...
Schneider LD, Stevens J, Husain AM, Ito D, Fuller DS, Zee PC, Macfadden W   +6 more
doaj  

Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study

Neurology and Therapy
Logan D. Schneider, Chad M. Ruoff, David T. Plante, Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Sarah Akerman, Jessica K. Alexander, Marisa Whalen, Alyssa Cairns   +10 more
openaire   +2 more sources

Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1

Internal Medicine Journal, EarlyView.
Abstract A clinical diagnosis of narcolepsy type 1 can be challenging, particularly in relation to cataplexy. Despite its specificity, cerebrospinal fluid (CSF) orexin testing is under‐utilised in Australasia. We describe the use of CSF orexin testing in 15 clinically indicated patients from two sleep centres, highlighting its utility in the ...
Mario Fernando, Gianluca Cotta, Samantha Kung, Grace Garden, Jian Eu Tai, Elie Matar, Brendon Yee, Claire Ellender, Sheila Sivam   +8 more
wiley   +1 more source

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

iSPHYNCS: Unsupervised Clustering in Questionnaires and Metadata Reveals Distinct Subtypes in the Narcolepsy Borderland

Journal of Sleep Research, EarlyView.
Study overview and clustering results in the iSPHYNCS cohort. Participant demographics are summarized in a baseline table. Questionnaire data and metadata were processed through an unsupervised clustering pipeline. A Sankey plot illustrates individual assignment across clusters by diagnostic group.
Rafael Morand, Livia Fregolente, Julia van der Meer, Elena S. Wenz, Annina Helmy, Lorenzo Brigato, Jan D. Warncke, Kseniia Zub, Ramin Khatami, Zhongxing Zhang, Sigrid von Manitius, Silvia Miano, Jens Acker, Mathias Strub, Ulf Kallweit, Gert Jan Lammers, Athina Tzovara, Claudio L. A. Bassetti, Stavroula Mougiakakou, Markus H. Schmidt   +19 more
wiley   +1 more source